Literature DB >> 31059222

Deciphering the Allosteric Binding Mechanism of the Human Tropomyosin Receptor Kinase A ( hTrkA) Inhibitors.

Govindan Subramanian1, Paul D Johnson1, Theresa Zachary1, Nicole Roush1, Yaqi Zhu1, Scott J Bowen1, Ann Janssen1, Brian A Duclos1, Tracey Williams1, Christopher Javens1, Nancy Dekki Shalaly2, Daniel Martinez Molina2, Arthur J Wittwer3, Jeffrey L Hirsch3.   

Abstract

Access to cryptic binding pockets or allosteric sites on a kinase that present themselves when the enzyme is in a specific conformational state offers a paradigm shift in designing the next generation small molecule kinase inhibitors. The current work showcases an extensive and exhaustive array of in vitro biochemical and biophysical tools and techniques deployed along with structural biology efforts of inhibitor-bound kinase complexes to characterize and confirm the cryptic allosteric binding pocket and docking mode of the small molecule actives identified for hTrkA. Specifically, assays were designed and implemented to lock the kinase in a predominantly active or inactive conformation and the effect of the kinase inhibitor probed to understand the hTrkA binding and hTrkB selectivity. The current outcome suggests that inhibitors with a fast association rate take advantage of the inactive protein conformation and lock the kinase state by also exhibiting a slow off-rate. This in turn shifts the inactive/active state protein conformational equilibrium cycle, affecting the subsequent downstream signaling.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31059222     DOI: 10.1021/acschembio.9b00126

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  4 in total

1.  Synthetic inhibitor leads of human tropomyosin receptor kinase A (hTrkA).

Authors:  Govindan Subramanian; Rajendran Vairagoundar; Scott J Bowen; Nicole Roush; Theresa Zachary; Christopher Javens; Tracey Williams; Ann Janssen; Andrea Gonzales
Journal:  RSC Med Chem       Date:  2020-01-10

Review 2.  Evaluation of Substituted Pyrazole-Based Kinase Inhibitors in One Decade (2011-2020): Current Status and Future Prospects.

Authors:  Mohammed I El-Gamal; Seyed-Omar Zaraei; Moustafa M Madkour; Hanan S Anbar
Journal:  Molecules       Date:  2022-01-05       Impact factor: 4.411

Review 3.  Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers.

Authors:  Tingting Jiang; Guan Wang; Yao Liu; Lu Feng; Meng Wang; Jie Liu; Yi Chen; Liang Ouyang
Journal:  Acta Pharm Sin B       Date:  2020-05-23       Impact factor: 11.413

Review 4.  Pyrazolyl-Ureas as Interesting Scaffold in Medicinal Chemistry.

Authors:  Chiara Brullo; Federica Rapetti; Olga Bruno
Journal:  Molecules       Date:  2020-07-29       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.